Truist Financial Corp grew its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 13.9% in the 4th ...

Savant Capital LLC lowered its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 14.4% in the 4th ...

IDEXX Laboratories, Inc.’s IDXX fourth-quarter performance was driven by the consistent strong performance of the Companion Animal Group (“CAG”) segment. Solid performance in the international markets ...

Veterinary Molecular Diagnostics MarketThe global veterinary molecular diagnostics market is expected to experience significant growth, with an estimated value of USD 194.47 million in 2023, and is ...

Conestoga Capital Advisors, an asset management company, released its fourth-quarter 2024 investor letter. A copy of the ...

A substantial insider sell was reported on February 10, by M. Anne Szostak, Director at IDEXX Laboratories IDXX, based on the recent SEC filing. What Happened: Szostak's recent mo ...

IDEXX Laboratories is poised for growth in the pet healthcare market. Check out why I see a 50% upside in IDXX stock by FY27.

The S&P 500 fell 0.8% on Monday, Feb. 3, as investors reacted to tariffs on major U.S. trading partners while awaiting key earnings and labor market data.

Corporate and Companion Animal Group Finance; and John Ravis, Vice President, Investor Relations. IDEXX would like to preface the discussion today with a caution regarding forward-looking statements.

IDEXX Laboratories exceeded fourth-quarter profit and revenue estimates on sales of its animal testing products and price increases.